

WHO SHOULD ATTEND

This educational activity is specifically designed for hematologists, oncologists, and other physicians, clinicians, physicians-in-training, and healthcare professionals (oncology nurses, oncology pharmacists, physician assistants) involved and/or interested in the therapeutic management of patients with multiple myeloma.

CHAIR
James R. Berenson, MD
Institute for Myeloma and Bone Cancer Research
West Hollywood, California
A BREAKFAST SYMPOSIUM DURING
THE LYMPHOMA & MYELOMA 2010 CONGRESS

CORPORATE SUPPORT
The following company has provided an
educational grant in support of this symposium:



OCTOBER 22, 2010
WALDORF-ASTORIA, STARLIGHT ROOF
NEW YORK, NEW YORK

TO THE BONE MARROW... AND BEYOND!

Optimizing Bone-Related and
Anti-Tumor Properties of
Bisphosphonates for Patients
with Multiple Myeloma

CONTINUING MEDICAL EDUCATION

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum of 1.25 of *AMA PRA Category 1 Credits*SM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

TO THE BONE MARROW... AND BEYOND!

Optimizing Bone-Related and Anti-Tumor Properties of Bisphosphonates for Patients with Multiple Myeloma

REGISTRATION

Registration is complimentary to attendees of the Lymphoma & Myeloma 2010 Congress.

SYMPOSIUM ORGANIZER

Imedex
4325 Alexander Drive
Alpharetta, Georgia
30022-3740, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
www.imedex.com

SCIENTIFIC AGENDA

- 6:15 am Breakfast served
- 6:30 am Welcome & pre-activity knowledge/competence assessment
James R. Berenson, MD
- 6:35 am Bisphosphonates in the treatment of bone disease
James R. Berenson, MD
- 6:45 am Monitoring therapy and mitigating side effects: Acute phase reaction, renal dysfunction and ONJ
Noopur Raje, MD
- 6:55 am Beyond the bone: Anti-tumor effects of bisphosphonates in multiple myeloma
James R. Berenson, MD
- 7:05 am Panel discussion: What patients with plasma dyscrasias should be treated with anti-bone resorptive therapy? Are the anti-tumor effects of bisphosphonates enough for a change in treatment strategy?
James R. Berenson, MD
Matthew T. Drake, MD, PhD
Noopur Raje, MD
G. David Roodman, MD, PhD
- 7:20 am Case Presentation with Virtual Patient Point-Counterpoint: How long and what schedule to use in continuing bisphosphonates?
• Point: Push on
G. David Roodman, MD, PhD
• Counterpoint: Time to move on
Matthew T. Drake, MD, PhD
- 7:35 am Emerging new therapeutic approaches to myeloma bone disease
G. David Roodman, MD, PhD
- 7:45 am Post-activity knowledge/competence assessment & closing remarks
- 7:50 am Adjourn

OCTOBER 22, 2010
WALDORF-ASTORIA, STARLIGHT ROOF
NEW YORK, NEW YORK

OBJECTIVES

After participating in this educational activity, participants should be able to:

- Discuss three known effects of bisphosphonates in multiple myeloma (MM)
- List two practical recommendations for duration and intensity of bisphosphonates in MM
- Describe at least one mechanism surrounding bisphosphonate effects both within and outside the bone environment in MM
- Comment on the clinical utility of bone resorption for patients with MM
- Implement at least two prevention strategies to mitigate risk of side effects for patients using bisphosphonate therapies
- List two anti-tumor properties of bisphosphonate compounds in MM
- Identify novel bisphosphonate combinations under investigation that may lead to improved outcomes for patients with MM
- Comment on the clinical context of ongoing trials of bisphosphonates in MM

FACULTY

James R. Berenson, MD
Institute for Myeloma and Bone Cancer
West Hollywood, California

Matthew T. Drake, MD, PhD
Mayo Clinic College of Medicine
Rochester, Minnesota

Noopur Raje, MD
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

G. David Roodman, MD, PhD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania